While Lilly’s position in the obesity market and wider GLP-1 space has remained largely unshakeable in recent months, a crack in the company’s armor may be forming, according to at least one analyst.

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug. By Rebecca Robbins Eli Lilly reached a deal on Tuesday to buy Centessa ...

Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug ...

Eli Lilly’s LLY-1.65%decrease; red down pointing triangle experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant improvements in weight ...

One of Eli Lilly & Co.’s most highly anticipated experimental medicines helped diabetic patients lose more weight than any drug currently on the market, underscoring its potential in the increasingly ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Diabetes patients taking ...

With shares up 20% over the past 12 months, Eli Lilly appears to have come out on top in the battle to dominate the weight-loss drug market, with rival Novo Nordisk sinking 52% over the same period.

Matthew Herper covers medical innovation — both its promise and its perils. Everything changed with a white envelope. On Dec. 20, 2018, Jacob Van Naarden, the chief operating officer of a biotech ...

The healthcare sector is selling off in lockstep with the broader market. Eli Lilly’s growth is heavily dependent on weight loss drugs. The healthcare sector is reasonably valued. Eli Lilly makes many ...

With the success of GLP-1-based drugs, pharmaceutical companies are aggressively pursuing next-generation versions that could provide patients with more refined options for controlling diabetes and ...

As Eli Lilly begins to take the next generation of obesity drugs to regulators this year, a lower-profile collaboration suggests the Big Pharma still thinks it could find future success from a more ...

One of these companies' lineup and pipeline within weight management and outside look much stronger. Valuation does not tip the scale in the other's favor. Eli Lilly's weight loss medicine, Zepbound, ...